Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Platzbecker

Showing results (91-100 of 482) with videos related to

Pageof 49
Sort By:
Psycho-Oncology|September 11, 2023
New progress in an old debate? Applying the DSM-5 criteria to assess traumatic events and stressor-related disorders in cancer survivorsFranziska Springer, Michael Friedrich, Katharina Kuba, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 13, 2018
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 StudyValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
Haematologica|October 29, 2017
Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathwayEkaterina Balaian, Manja Wobus, Heike Weidner, et al.
Blood Advances|May 23, 2022
Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remissionMadlen Jentzsch, Lara Bischof, Donata Backhaus, et al.
Cytometry. Part B, Clinical Cytometry|August 14, 2021
Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impactUta Oelschlaegel, Lorenz Oelschlaeger, Malte von Bonin, et al.
Blood Reviews|June 5, 2021
Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learnedEsther N Oliva, Uwe Platzbecker, Pierre Fenaux, et al.
Annals of Hematology|February 13, 2008
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromesAristoteles Giagounidis, Pierre Fenaux, Ghulam J Mufti, et al.
Experimental Hematology|June 19, 2012
Impact of lenalidomide on the functional properties of human mesenchymal stromal cellsManja Wobus, Gwendolin Benath, Ruben A Ferrer, et al.
Basic Research in Cardiology|November 10, 2022
Clonal hematopoiesis and cardiovascular disease: deciphering interconnectionsAnna Stein, Klaus Metzeler, Anne Sophie Kubasch, et al.
Blood|May 10, 2013
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AMLNona Shayegi, Michael Kramer, Martin Bornhäuser, et al.
Pageof 49

Showing results (91-100 of 482) with videos related to

Sort By:
Pageof 49
Psycho-Oncology|September 11, 2023
New progress in an old debate? Applying the DSM-5 criteria to assess traumatic events and stressor-related disorders in cancer survivorsFranziska Springer, Michael Friedrich, Katharina Kuba, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 13, 2018
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 StudyValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
Haematologica|October 29, 2017
Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathwayEkaterina Balaian, Manja Wobus, Heike Weidner, et al.
Blood Advances|May 23, 2022
Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remissionMadlen Jentzsch, Lara Bischof, Donata Backhaus, et al.
Cytometry. Part B, Clinical Cytometry|August 14, 2021
Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impactUta Oelschlaegel, Lorenz Oelschlaeger, Malte von Bonin, et al.
Blood Reviews|June 5, 2021
Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learnedEsther N Oliva, Uwe Platzbecker, Pierre Fenaux, et al.
Annals of Hematology|February 13, 2008
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromesAristoteles Giagounidis, Pierre Fenaux, Ghulam J Mufti, et al.
Experimental Hematology|June 19, 2012
Impact of lenalidomide on the functional properties of human mesenchymal stromal cellsManja Wobus, Gwendolin Benath, Ruben A Ferrer, et al.
Basic Research in Cardiology|November 10, 2022
Clonal hematopoiesis and cardiovascular disease: deciphering interconnectionsAnna Stein, Klaus Metzeler, Anne Sophie Kubasch, et al.
Blood|May 10, 2013
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AMLNona Shayegi, Michael Kramer, Martin Bornhäuser, et al.
Pageof 49